Deininger M
J Natl Compr Canc Netw. 2005 Nov ; 3(6): 757-68

Imatinib, a specific small molecule inhibitor of the Abl kinase, has become the standard drug therapy for chronic myelogenous leukemia in all phases. More than 80% of newly diagnosed patients with chronic phase attain a complete cytogenetic response (CCR). Although remissions in patients with early disease are generally durable, acquired resistance after an initial response is common in advanced disease. Reactivation of Bcr-Abl signaling is almost invariably present at the time of relapse, consistent with re-establishment of the initial pathogenetic mechanism. Mutations in the kinase domain (KD) of Bcr-Abl that impair drug binding and increased _expression_ of Bcr-Abl have been identified as major mechanism of acquired drug resistance. The fact that Bcr-Abl remains central to disease pathogenesis at the time of relapse implies that it also remains the optimal drug target.
--
Posted by Rob to CML Newswire: Medical And Technical News On Chronic Myelogenous Leukemia at 12/17/2005 04:57:22 PM


New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com

Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com

CML (Chronic Myelogenous Leukemia Support List)
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com

Post Message: [email protected]
Subscribe:  [EMAIL PROTECTED]
Unsubscribe:  [EMAIL PROTECTED]
Change To No Mail/Web: [EMAIL PROTECTED]
Change To Digest: [EMAIL PROTECTED]
Change To Email: [EMAIL PROTECTED]
List Help: [EMAIL PROTECTED] 
CML Group Web Site http://groups.yahoo.com/group/CML




SPONSORED LINKS
Chronic myelogenous leukemia Leukemia treatment Cml


YAHOO! GROUPS LINKS




Reply via email to